Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$25.92 USD
-0.76 (-2.85%)
Updated Jun 14, 2024 03:59 PM ET
After-Market: $25.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
MIRM 25.92 -0.76(-2.85%)
Will MIRM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MIRM
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
Mirum Pharmaceuticals presents long-term data from LIVMARLI studies
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference